18 completed, 5 unknown, 4 recruiting, 3 active not recruiting. 33 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 33 | Completed 18, Unknown 5, Recruiting 4, Active not recruiting 3, Not yet recruiting 2, Terminated 1 |
| Phase 2 | 6 | Recruiting 3, Completed 2, Unknown 1 |
Follow Dengue: new trials by email Literature Review of Dengue trials Research Report on Dengue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| Therapeutics for Moderate and Severe Dengue Placebo, Dexamethasone, N-Acetylcysteine - Dengue, Severe Dengue | Phase 3 | Not yet recruiting | Oxford University Clinical Research Unit, Vietnam | 8800 | 2026-10-01 | 2026-04-21 |
| Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 600 | 2026-09-01 | 2026-10-13 |
| A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) CP-COV03, Placebo - Dengue | Phase 2 / Phase 3 | Recruiting | Hyundai Bioscience Co., Ltd. | 210 | 2026-04-09 | 2026-07-10 |
| Butantan-DV Vaccine in Elderly Populations (DEN-04-IB) Dengue 1,2,3,4 (attenuated) vaccine - Dengue | Phase 3 | Active not recruiting | Butantan Institute | 997 | 2026-03-03 | 2026-11-10 |
| A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) TDV, Placebo - Dengue Fever | Phase 3 | Active not recruiting | Takeda | 800 | 2026-01-20 | 2026-09-22 |
| A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults Tetravalent Dengue Vaccine (TDV) - Dengue Fever | Phase 3 | Active not recruiting | Takeda | 496 | 2025-11-07 | 2026-07-17 |
| A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers TDV, Placebo - Dengue Fever | Phase 3 | Recruiting | Takeda | 212 | 2025-06-16 | 2026-06-29 |
| Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients Montelukast, Montelukast Placebo - Dengue, Montelukast | Phase 2 / Phase 3 | Recruiting | Phramongkutklao College of Medicine and Hospital | 82 | 2025-01-31 | 2025-05-29 |
| A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan TDV, Placebo - Dengue Fever | Phase 2 / Phase 3 | Completed | Takeda | 187 | 2025-01-31 | 2025-12-30 |
| The Comparative Efficacy of Standard Treatment Plus Ribavirin vs Standard Treatment Alone in Preventing Clinically Significant Hemorrhage in Patients With Dengue Fever Ribavirin, Standard Treatment - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Completed | Khyber Medical University Peshawar | 284 | 2024-12-17 | 2025-06-26 |
| Efficacy and Safety of Carica Papaya in Dengue Fever: A Randomised Clinical Trial Carica Papaya Leaf Extract, Placebo - Dengue | Phase 3 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 250 | 2023-10-01 | 2026-06-16 |
| Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years 9vHPV Vaccine, Dengue Tetravalent Vaccine (TDV) - Dengue Fever | Phase 3 | Completed | Takeda | 614 | 2021-05-15 | 2024-02-07 |
| Effect of Montelukast in Preventing Dengue With Warning Signs in Dengue Patients Montelukast, Placebo - Dengue, Dengue With Warning Signs | Phase 2 / Phase 3 | Completed | Phramongkutklao College of Medicine and Hospital | 358 | 2021-01-15 | 2023-07-18 |
| Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo - Dengue Fever | Phase 3 | Completed | Takeda | 365 | 2019-11-12 | 2026-07-30 |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults Tetravalent Dengue Vaccine (TDV) - Dengue Fever | Phase 3 | Completed | Takeda | 200 | 2019-03-28 | 2021-06-07 |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults YF-17D, TDV, Placebo - Dengue | Phase 3 | Completed | Takeda | 900 | 2018-02-28 | 2020-10-08 |
| Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue TAK-003, Placebo - Dengue Fever | Phase 3 | Completed | Takeda | 923 | 2018-02-12 | 2020-10-20 |
| Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) Tetravalent Dengue Vaccine (TDV), Placebo - Dengue | Phase 3 | Completed | Takeda | 400 | 2017-12-14 | 2019-08-15 |
| Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects CYD Dengue Vaccine, Tdap: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine adsorbed, Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed - Dengue Fever, Dengue Hemorrhagic Fever | Phase 3 | Terminated | Sanofi Pasteur, a Sanofi Company | 688 | 2016-12-19 | 2022-03-25 |
Showing 20 of 33. Sign in to see all of them.
Severe Dengue (13) · Flavivirus Infections (2) · Arbovirus Infections (1) · Chikungunya Fever (1) · Encephalitis, Japanese (1) · Hemorrhage (1) · Hemorrhagic Fevers, Viral (1) · Malaria (1) · Mosquito-Borne Diseases (1) · RNA Virus Infections (1) · Vector Borne Diseases (1) · Yellow Fever (1)
Flaviviridae Infections (33) · Infections (33) · Virus Diseases (33) · Arbovirus Infections (32) · Hemorrhagic Fevers, Viral (32) · Mosquito-Borne Diseases (32) · RNA Virus Infections (32) · Vector Borne Diseases (32) · Flavivirus Infections (31) · Alphavirus Infections (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Infections (1) · Central Nervous System Viral Diseases (1) · Encephalitis (1)
Dengue Vaccines (7) · Vaccines (4) · Measles-Mumps-Rubella Vaccine (2) · Sodium Chloride (2) · montelukast (2) · Acetylcysteine (1) · Albumins (1) · Dexamethasone (1) · Emetine (1) · Fluid Therapy (1) · Haemophilus Vaccines (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 (1) · Ivermectin (1) · Pentavac (1)
Takeda (10) · Sanofi Pasteur, a Sanofi Company (8) · Butantan Institute (3) · Phramongkutklao College of Medicine and Hospital (2) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Hyundai Bioscience Co., Ltd. (1) · Innogene Kalbiotech Pte. Ltd (1) · Johns Hopkins University (1) · Khyber Medical University Peshawar (1) · London School of Hygiene and Tropical Medicine (1) · Mahidol University (1) · Oxford University Clinical Research Unit, Vietnam (1) · Sanofi (1) · Universitas Indonesia (1)
Thailand (8) · Brazil (6) · Mexico (5) · United States (5) · Colombia (4) · Indonesia (4) · Malaysia (4) · Philippines (3) · Vietnam (3) · Australia (2) · Bangladesh (2) · Nepal (2) · Peru (2) · Argentina (1) · Honduras (1)
Fernanda C Boulos, MD, PhD (2) · Worapong Nasomsong, MD (2) · Akhtar Sherin, MBBS,MHR,PHD (1) · Dadang H Somasetia, SpA(K), MKes (1) · Kunchok Dorjee, MBBS, PhD (1) · Nigel Hill, PhD (1) · Noman Arif, MBBS (1) · Panisadee Avirutnan, MD, PhD. (1) · Said Amin, MBBS,FCPS (1) · Sheraz Fazid, MBBS,MPH (1) · Sophie Yacoub, MD., PhD. (1)
PMID 40099800, PMID 39116904, PMID 26214039, PMID 27007959, PMID 27418050, PMID 27459266, PMID 28871961, PMID 29300876, PMID 29897841, PMID 33212068, PMID 33822015, PMID 34003796, PMID 34219653, PMID 35659904, PMID 38294972, PMID 23967083, PMID 24135573, PMID 25018116, PMID 25189175, PMID 25365753, PMID 26279339, PMID 26614588, PMID 26639777, PMID 27414655, PMID 27532617, PMID 27601343, PMID 28590795, PMID 28598256, PMID 28968794, PMID 29408333, PMID 32040014, PMID 32220283, PMID 32497524, PMID 33124646, PMID 33992441, PMID 34117198, PMID 34131423, PMID 34250977, PMID 36888687, PMID 37321235, PMID 37846724, PMID 37884415, PMID 38306389, PMID 39255380, PMID 39308445, PMID 39350232, PMID 39356094, PMID 40749348, PMID 41058426, PMID 41092804
2019 (3), 2014 (2), 2023 (2), 2018 (1)